Cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
Line 250: Line 250:
|bgcolor= "LightBlue"; style="text-align:center;|C
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
|-
|bgcolor="LightGray"|2. The use of validated [[SCD]] [[algorithms]]/scores as aids to the shared decision-making when offering [[ICD implantation]], where available is
|bgcolor="LightGray"|2. The use of validated [[SCD]] [[algorithms]]/scores as aids to the shared decision-making when offering [[ICD implantation]], where available is recommended in [[patients]] with [[HCM]].
recommended in [[patients]] with [[HCM]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
|-

Revision as of 04:50, 11 November 2023

Cardiomyopathy
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy

CDC on Cardiomyopathy

Cardiomyopathy in the news

Blogs on Cardiomyopathy

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub,MD; Mahshid Mir, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3], Raviteja Guddeti, M.B.B.S. [4]; Edzel Lorraine Co, DMD, MD[5]


Synonyms and keywords: Myocardiopathy; cardiac muscle disease; heart muscle disease.

Overview

Historical Perspective

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Guidelines


2023 ESC Guideline Recommendations [1]

Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams

Class I Level of Evidence
1. It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the diagnosis and management of cardiomyopathies. C
2. Timely and adequate preparation for transition of care from pediatric to adult services, including joint consultations, is recommended in all adolescents with cardiomyopathy. C

Recommendations for Diagnostic Work-up in Cardiomyopathies

Class I Level of Evidence
1. It is recommended that all patients with suspected or established cardiomyopathy undergo systematic evaluation using a multiparametric approach that includes clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging. C
2. It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation family tree is created to aid in diagnosis, provide clues to underlying etiology, determine inheritance pattern, and identify at- risk relatives C

Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies

Class I Level of Evidence
1. Routine (first-level) laboratory tests are recommended in all patients with suspected or confirmed cardiomyopathy to evaluate etiology, assess disease severity, and aid in detection of extra-cardiac manifestations and assessment of secondary organ dysfunction. C

Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies

Class I Level of Evidence
1. A comprehensive evaluation of cardiac dimensions and LV and RV systolic (global and regional) and LV diastolic function is recommended in all patients with cardiomyopathy at initial evaluation, and during follow-up, to monitor disease progression and aid risk stratification and management. B

Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies

Class I Level of Evidence
1. Contrast-enhanced CMR is recommended in patients with cardiomyopathy at initial evaluation. B

Recommendations for Computed Tomography and Nuclear Imaging

Class I Level of Evidence
1. DPD/PYP/HMDP bone-tracer scintigraphy is recommended in patients with suspected ATTR-related cardiac amyloidosis to aid diagnosis. B

Recommendations for Genetic Counselling and Testing in Cardiomyopathies

Genetic Counselling
Class I Level of Evidence
1. Genetic counselling, provided by an appropriately trained healthcare professional and including genetic education to inform decision-making and psychosocial support, is recommended for families with an inherited or suspected inherited cardiomyopathy, regardless of whether genetic testing is being considered. B
2. It is recommended that genetic testing for cardiomyopathy is performed with access to a multidisciplinary team, including those with

expertise in genetic testing methodology, sequence variant interpretation, and clinical application of genetic testing, typically in a specialized cardiomyopathy service or in a network model with access to equivalent expertise.

B
3. Pre- and post-test genetic counselling is recommended in all individuals undergoing genetic testing for cardiomyopathy. C
Index Patients
Class I Level of Evidence
1.Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis,

prognostication], therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.

B
2. Genetic testing is recommended for a deceased individual identified to have cardiomyopathy at post-mortem if a genetic diagnosis would facilitate management of surviving relatives. C
Family Members
Class I Level of Evidence
1. It is recommended that cascade genetic testing, with pre- and post-test counselling, is offered to adult at-risk relatives if a confident genetic diagnosis (i.e. a P/LP variant) has been established in an individual with cardiomyopathy in the family (starting with first-degree relatives if available, and cascading out sequentially). B
Class III Level of Evidence
2. Diagnostic genetic testing is not recommended in a phenotype-negative relative of a patient with cardiomyopathy in the absence of a confident genetic diagnosis (i.e. a P/LP variant) in the family. C

Recommendations for Cardiac Implantation in Patients with Cardiomyopathy

Class I Level of Evidence
1. Orthotopic cardiac transplantation is recommended for eligible cardiomyopathy patients with advanced heart failure (NYHA class III–IV) or intractable ventricular arrhythmia refractory to medical/invasive/device therapy, and who do not have absolute contraindications. C
2. It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation family tree is created to aid in diagnosis, provide clues to underlying etiology, determine inheritance pattern, and identify at- risk relatives C

Recommendations for Management of Atrial Fibrillation and Atrial Flutter in Patients with Cardiomyopathy

Anticoagulation
Class I Level of Evidence
1. Oral anticoagulation in order to reduce the risk of stroke and thromboembolic events is recommended in all patients with HCM or cardiac amyloidosis and AF or atrial flutter (unless contraindicated). B
2. Oral anticoagulation to reduce the risk of stroke and thromboembolic events is recommended in patients with DCM, NDLVC, or ARVC, and AF or atrial flutter with a CHA2DS2-VASc score ≥2 in men or ≥3 in women. B
Control of symptoms and heart failure
Class I Level of Evidence
1.Atrial fibrillation catheter ablation is recommended forrhythm control after one failed or intolerant class I or III AAD to improve symptoms of AF recurrences in patients with paroxysmal or persistent AF and cardiomyopathy. B
2. Atrial fibrillation catheter ablation is recommended to reverse LV dysfunction in AF patients with cardiomyopathy when a

tachycardia-induced component is highly probable, independent of their symptom status.

B
Comorbidities and associated risk factor management
Class I Level of Evidence
1. Modification of an unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity in patients with cardiomyopathy. B

Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy

General Recommendations
Class I Level of Evidence
1. Implantation of a cardioverter defibrillator is only recommended in patients who have an expectation of good qualitysurvival >1 year. C
2. It is recommended that ICD implantation be guided by shared decision-making that: C
3. It is recommended that prior to ICD implantation, patients are counselled on the risk of inappropriate shocks, implant complications, and the social, occupational, and driving implications of the device. C
Class III Level of Evidence
4. It is not recommended to implant an ICD in patients with incessant ventricular arrhythmias until the ventricular arrhythmia is controlled. C
Secondary Prevention
Implantation of an ICD is recommended:
Class I Level of Evidence
B
C
Primary Prevention
Class I Level of Evidence
1. Comprehensive SCD risk stratification is recommended in all cardiomyopathy patients who have not suffered a previous cardiac arrest/ sustained ventricular arrhythmia at initial evaluation and at 1–2 year intervals, or whenever there is a change in clinical status. C
2. The use of validated SCD algorithms/scores as aids to the shared decision-making when offering ICD implantation, where available is recommended in patients with HCM. B
Choice of ICD
Class I Level of Evidence
1. When an ICD is indicated, it is recommended to evaluate whether the patient could benefit from CRT. A


2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy [2]

Case Studies

Case #1

de:Kardiomyopathie nl:Cardiomyopathie no:Kardiomyopati simple:Cardiomyopathy sr:Кардиомиопатија sv:Hjärtmuskelsjukdom

Template:WikiDoc Sources

  1. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C; et al. (2023). "2023 ESC Guidelines for the management of cardiomyopathies". Eur Heart J. 44 (37): 3503–3626. doi:10.1093/eurheartj/ehad194. PMID 37622657 Check |pmid= value (help).
  2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P; et al. (2020). "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 142 (25): e558–e631. doi:10.1161/CIR.0000000000000937. PMID 33215931 Check |pmid= value (help).